Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethinylestradiol + cyproterone acetate is a combined oral contraceptive pill frequently used in the management of polycystic ovary syndrome (PCOS). It consists of ethinylestradiol, a synthetic estrogen, and cyproterone acetate, a synthetic progestogen with potent anti-androgenic activity. The combination works by suppressing the secretion of pituitary gonadotropins, thereby inhibiting ovarian androgen production, while the cyproterone component directly blocks androgen receptors in target tissues. This dual action effectively treats clinical manifestations of hyperandrogenism, such as acne and hirsutism, and regulates menstrual cycles in women with PCOS. Chongqing Medical University has conducted comparative clinical trials evaluating its efficacy against metformin regarding insulin sensitivity and ovulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinylestradiol + cyproterone acetate.